Prognosis for Metastatic Colon Cancer

Introduction to Prognosis

The American Society of Clinical Oncology and other organizations acknowledge that metastatic colorectal cancer to liver and lungs without treatment carries a poor prognosis, with most patients succumbing to the disease within a year, and the liver is the most common site of metastatic disease, with more than half of patients who die from colorectal cancer having liver metastases at autopsy 2
The presence of both liver and lung metastases indicates a more disseminated disease state, though these sites are considered more favorable than other metastatic locations 3

With modern systemic chemotherapy regimens, median overall survival improves to approximately 19-24 months, and 5-year survival rates of 10-20% are possible, particularly if the metastases become resectable after treatment, according to the National Comprehensive Cancer Network 1
If metastases become resectable after chemotherapy response, long-term survival or even cure can be attained in 20-45% of patients who undergo complete surgical resection or ablation of their metastases, as reported by the American Society of Clinical Oncology 1, 3
Resection of liver metastases offers 5-year disease-free survival rates of approximately 20%, and resection of lung metastases offers 25-35% 5-year survival rates in carefully selected patients, as stated by the Society of Surgical Oncology 2, 4

Conversion to resectable disease through neoadjuvant chemotherapy can significantly improve prognosis, and modern treatment approaches include combination chemotherapy, targeted therapies based on molecular profiling, and local treatments including surgery, thermal ablation, or stereotactic body radiotherapy for oligometastatic disease, according to the European Society for Medical Oncology 1, 3, 4
For patients with unresectable disease, the goal of treatment is to provide long-term disease control and potentially improved overall survival, as recommended by the National Comprehensive Cancer Network 3

Synchronous liver metastases generally carry a worse prognosis than metachronous metastases, and the presence of both liver and lung metastases indicates more extensive disease spread, though these sites are considered more favorable than other metastatic locations, as reported by the American Joint Committee on Cancer 2, 3, 5